Arimidex is an aromatase inhibitor that prevents steroids that are prone to aromatization from converting to estrogen. Unlike suicidal inhibitors, arimidex does not reduce the level of aromatase enzyme in the body. It can take up to four days to reach maximal suppression of estrogen levels with this drug1. Suppression of estrogen production up to 90% has been reported with arimidex1. The potency of this aromatase inhibitor is apparent in the fact that it is taken in such a low dose. AAS users take aromatase inhibitors to try to prevent the rise in estrogen when using aromatizable steroids, primarily to prevent gynecomastia. Arimidex has been shown to reduce breast tenderness associated with gynecomastia without reducing the size of the tissue2. Unlike other aromatase inhibitors, arimidex has been shown to not alter lipid profilesor to affect adrenal steroid synthesis1. Many of the name brand aromatase inhibitors are sold on the gray market over the internet through “research” companies and are sold in either pill, powder or liquid form but the quality of these items is not assured.
1. Buzdar AU: Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res. Jan;9(1 Pt 2):468S-72S, 2003
2. Riepe FG, Baus I, Wiest S, Krone N, Sippell WG, Partsch CJ: Treatment of pubertal gynecomastia with the specific aromatase inhibitor anastrozole. Horm Res. 62(3):113-8. Epub 2004 Jul 20, 2004